AUTHORS
Fieke W Hoff, MD, PhD, Aishwarya Sahasrabudhe, Ph.D.2, Curtis Lachowiez, MD3, Wei Ying Jen, BM BCh, FRCPath4, Alexander Smith5, Hsin-Yun Lin, PhD6, Leticia Campoverde, MD7, Warren Fiskus, PhD8, Christopher P Mill, PhD9, Daniel Yuan10, Jillian Mullin11, Sanam Loghavi, MD12, Katelyn Gutowsky13, Hiam Abdel-Salam, M.S14, Danielle Hammond, MD15, Kelly Sharon Chien, MD16, Andrew Frelinger, PhD17, Alan Cantor, MD, PhD18, Katrin Ericson, Ph.D.19, Anupriya Agarwal, PhD20, Courtney DiNardo, MD, MSCE21
AFFILIATIONS
1 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 Oregon Health and Science University, Oregon, United States
3 Oregon Health and Science University, Oregon, United States
4 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 Oregon Health and Science University, Oregon, United States
6 Oregon Health and Science University, Oregon, United States
7 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 Boston Children's Hospital, Boston, United States
11 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 Oregon Health and Science University, Oregon, United States
14 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 Boston Children's Hospital, Boston, United States
18 Boston Children's Hospital, Boston, United States
19 RUNX1 Research Program, Santa Barbara, United States
20 Oregon Health and Science University, Oregon, United States
21 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background: RUNX1 familial platelet disorder (RUNX1-FPD) is caused by germline pathogenic mutations in RUNX1, a transcription factor essential for hematopoiesis. Most patients present with mild to moderate thrombocytopenia and/or platelet dysfunction and are at increased lifetime risk of developing hematologic malignancies (HM). RUNX1-FPD is also associated with atopic and inflammatory conditions. Preclinical studies showed that hematopoietic stem cells from patients with RUNX1-FPD exhibit upregulation of the mTOR and PI3K pathways, and that in vivo treatment with sirolimus (SRL) increased megakaryopoiesis and platelet function. We report results of an open-label pilot “early intervention” study assessing preliminary safety and activity of low-dose SRL in patients with RUNX1-FPD.
Methods: Patients (≥18 years) were eligible if they had a confirmed pathogenic/likely pathogenic germline RUNX1 variant, no HM diagnosis, and a platelet count ≥ 50×109/L. Secondary somatic mutations were not exclusionary. Patients received SRL 2 mg PO daily for 6 months, followed by 6 months off therapy. The primary objective was to evaluate safety and tolerability. Secondary objectives included changes in platelet count and function, changes in the number of somatic mutations and variant allele frequency (VAF) and clonal evolution, bleeding assessment per ISTH-BAT score, and changes in mTORC1 pathway activity.
Results: As of July 2026, 6 patients have been enrolled. Median age was 55 years (range 34–67), and 50% were female. Median baseline platelet count was 110×109/L (range 81–160). All patients had normal hemoglobin (median 12.7; range 11.1-13.7) and total while blood cell count (median 6; range 4.6-22.3). The median RUNX1 VAF was 47% (range 29-50%). BCOR (n=4, median VAF 6%, range 5-50%) was the most common somatic co-mutation at baseline; one patient harbored a DNMT3A (VAF 5%) mutation. Five patients have completed 6 months of SRL treatment; 1 patient remains on SRL. All patients reported at least 1 adverse event (AE). No AEs resulted in dose modifications or treatment discontinuation. Most were grade 1 (n=26) or 2 (n=15); the most common AE were diarrhea (n=6), oral mucositis (n=6), and nausea (n=4). One patient developed grade 3 hemorrhoids. Two patients elected to continue with 1 mg SRL after completion of treatment due to improved symptoms.
Correlative studies were completed in 4 of 6 patients. SRL levels were measured after 1, 3, and 6 months of therapy, and were within the target range of 5-15 ng/mL in 11 of 16 (69%) samples; at 5 time points supratherapeutic levels were identified. Assessment of target inhibition by phospho-flow cytometry on blood samples of 1 patient demonstrated inhibition of mTOR pathway with reductions up to 1.5-fold in the median fluorescence intensity of downstream targets p4EBP1 and pS6 between baseline and EOT.
Although platelet counts did not significantly increase during treatment, platelet activation parameters improved significantly from baseline. Thrombin receptor activating peptide induced GPIIb-IIIa activation (%PAC-1-positive platelets) increased from 31% at baseline to 77% at EOT, and P-selectin-positive platelets increased from 19% to 49% at EOT. The median ISTH-BAT bleeding score decreased from 8 (range 3–15) at baseline to 5 (range 2-11) at EOT. A score of ≥ 5 in females and ≥ 4 in males was considered abnormal.
The effect of SRL therapy on myeloid differentiation was assessed in 4 patients. CD13+/CD14+ (monocytes) and CD33+/CD13+ (maturing/myeloid) populations decreased after treatment by 1.7-fold and 1.2-fold, respectively, and returned to baseline after SRL discontinuation.
Finally, we evaluated SRL effects on inflammatory symptoms and plasma cytokine levels over time. Levels of INF and TNF family cytokines decreased steadily during treatment. Inflammatory symptoms, including joint pain, also improved, with a median symptom score decreasing from 3.5 at baseline to 2.5 at EOT.
Discussion: Short-term treatment with SRL was safe and well tolerated in patients with RUNX1-FPD. Despite no significant change in platelet counts, SRL therapy enhanced platelet reactivity and function, reduced inflammatory cytokines, and reduced bleeding symptoms. None of the patients developed HM or thrombosis during therapy. These preliminary findings suggest potential clinical benefit of SRL in RUNX1-FPD. The protocol is being amended to enroll additional patients (NCT06261060).
DISCLOSURES
Fieke W Hoff, MD, PhD: No relevant conflicts of interest to declare.